Opening the way to new treatments for lung disease.

Pulmokine, a biopharmaceutical company, develops innovative drug therapies and makes new pulmonary research solutions available to the R&D community.

Researching a new inhalable treatment for Pulmonary Arterial Hypertension (PAH).

We are in the pre-clinical phases of a new paradigm for the treatment of Pulmonary Arterial Hypertension (PAH), addressing the underlying causes of the disease.

Become a Pulmokine strategic partner
at the preclinical stage.

Pulmokine is interested in strategic partnerships with leading pharmaceutical corporations, R&D firms, licensors and/or investors to take our breakthrough technologies into the next phases of clinical development.